Peru vs United States: The number of people with susceptibility test result for rifampicin
Peru
94.02
in 2021
United States
94.32
in 2021
Peru rank
55th
United States rank
53rd
The number of people with susceptibility test result for rifampicin over time
- Peru
- United States
How they compare
United States currently reports 94.32 against 94.02 in Peru, a difference of 0.3.
Across all 5 years both countries report, United States has been ahead every year.
Peru ranks 55th and United States ranks 53rd of 146 countries.
United States has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Peru | United States | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 76.94 | 90.97 | 14.03 | United States |
| 2020s | 82.99 | 94.51 | 11.52 | United States |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Peru or United States?
- United States, at 94.32 against 94.02 in Peru as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Peru and United States?
- 0.3, with United States ahead.
- How many years of comparable data are there for Peru and United States?
- 5 years are reported by both, from 2017 to 2021.
- How do Peru and United States rank globally for the number of people with susceptibility test result for rifampicin?
- Peru ranks 55th and United States ranks 53rd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.